Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.51 |
| ▸ | CDK2 | P24941 | 12/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998487 | 0.89 | GSK3B (0.52) | GSK3BCDK2CCNE1 | |
| SCHEMBL13309220 | 0.87 | GSK3B (0.47) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13885051 | 0.84 | GSK3B (0.65) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13998466 | 0.83 | CDK2 (0.69) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13998534 | 0.80 | GSK3B (0.65) | GSK3BCDK2CCNE1HSD17B10 | |
| SCHEMBL12952885 | 0.78 | GSK3B (0.76) | GSK3BCDK2CCNE1 | |
| SCHEMBL13998471 | 0.77 | GSK3B (0.48) | GSK3BCDK2CCNE1MAPT | |
| SCHEMBL13993126 | 0.77 | CDK2 (0.67) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL12953407 | 0.77 | CDK2 (0.46) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL14043298 | 0.77 | CDK2 (0.46) | GSK3BCDK2CHEK1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470695-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470695-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1534709-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007044401-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |